Gazyva, Gazyvaro (obinutuzumab) is an antibody pharmaceutical. Obinutuzumab was first approved as Gazyva on 2013-11-01. It is used to treat follicular lymphoma and lymphoid leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against B-lymphocyte antigen CD20.
|Indication||b-cell chronic lymphocytic leukemia, follicular lymphoma, lymphoid leukemia|
|Drug Class||Monoclonal antibodies: humanized, tumors as target|